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ABSTRACT: Expression of β-lactamase is the single most
prevalent determinant of antibiotic resistance, rendering
bacteria resistant to β-lactam antibiotics. In this article, we
describe the development of an antibiotic prodrug that
combines ciproﬂoxacin with a β-lactamase-cleavable motif.
The prodrug is only bactericidal after activation by β-
lactamase. Bactericidal activity comparable to ciproﬂoxacin is
demonstrated against clinically relevant E. coli isolates
expressing diverse β-lactamases; bactericidal activity was not
observed in strains without β-lactamase. These ﬁndings demonstrate that it is possible to exploit antibiotic resistance to
selectively target β-lactamase-producing bacteria using our prodrug approach, without adversely aﬀecting bacteria that do not
produce β-lactamase. This paves the way for selective targeting of drug-resistant pathogens without disrupting or selecting for
resistance within the microbiota, reducing the rate of secondary infections and subsequent antibiotic use.
■ INTRODUCTION
Antimicrobial drug resistance is a global health emergency,
threatening advances in many areas of medicine including
surgery, cancer chemotherapy, organ transplantation, and
survival of preterm infants.1,2 The most prevalent and
important resistance determinant is the β-lactamase enzyme,
which hydrolyzes members of the β-lactam class of antibiotic
(e.g., penicillin, cephalosporins, and carbapenems) and thereby
prevents engagement with their therapeutic targets the
penicillin-binding proteins (PBPs).3,4 Of particular concern
are the extended-spectrum β-lactamases (ESBLs) such as the
CTX-M class, which are able to cleave a wide range of clinically
relevant β-lactam antibiotics.5−7
Urinary tract infections (UTIs) are the most prevalent type
of bacterial infection globally. These infections have a high rate
of recurrence and can also lead to serious invasive infections
such as sepsis, particularly in the elderly.8,9 E. coli is the most
common causative organism (∼75% cases), of which ∼50% are
resistant to β-lactam antibiotics due to β-lactamase expres-
sion.8,10 As a consequence of the high rate of β-lactam
resistance in UTI pathogens, second-line, broad-spectrum
antibiotics such as ciproﬂoxacin are increasingly used
therapeutically.11,12 Unfortunately, these broad-spectrum anti-
biotics are associated with disruption to the beneﬁcial bacteria
that colonize the gastrointestinal tract and other surfaces,
known as the microbiota.13−17 This disruption can lead to
serious secondary infections by antibiotic-resistant bacteria
such as Clostridium dif f icle or fungi such as Candida albicans,
leading to colitis and thrush, respectively.13,18 This is because
antibiotics target conserved processes in bacteria such as cell
wall, protein, DNA or RNA biosynthesis, which not only occur
in the pathogens that cause infection but also in the members
of the microbiota.19,20
An additional complication associated with some second-
line therapeutics such as ciproﬂoxacin is host toxicity.
Ciproﬂoxacin holds two black box warnings, one for increased
risk of tendinitis and tendon rupture and one for exacerbation
of muscle weakness in myasthenia gravis suﬀerers.21 Addition-
ally, in 2015, the FDA oﬃcially recognized ﬂuoroquinolone-
associated disability (FQAD) as a syndrome. FQAD describes
a range of disabling and potentially permanent side eﬀects
including disturbances of tendons, joints, muscles, nerves, the
nervous system, and induction of type 2 diabetes.22,23 As a
result, strategies with the potential to mitigate host toxicity by
reducing exposure to ciproﬂoxacin are needed.
Given the drawbacks associated with broad-spectrum
antibiotics, eﬀorts have been made to limit their use.11,23−25
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However, these eﬀorts have had limited success with usage
rates increasing globally, particularly in low- and middle-
income countries.26 In part, this is due to a lack of access to
fast and eﬃcient diagnostic techniques and the need to
respond quickly to serious bacterial infections with eﬀective
and cost-eﬃcient treatment regimens that target a wide range
of diﬀerent bacterial pathogens.27 There is, therefore, a
pressing need to develop new therapeutics that kill a broad
range of diﬀerent pathogens without damaging the host
microbiota.
Since β-lactamase enzymes are not found in mammalian
cells, we hypothesized that we could exploit this enzyme as a
novel antibacterial target. Furthermore, β-lactamase expression
is prevalent among UTI pathogens, which can both colonize
the gut and cause infection of the GU tract.8,10 Consequently,
this represents an opportunity to selectively target disease-
causing bacteria without causing signiﬁcant disruption to the
microbiota or select for drug resistance as has been reported
for broad-spectrum antibiotics such as ciproﬂoxacin.28−30
Therefore, the aim of this work was to develop a small
molecule antibacterial agent that is selectively active against
bacteria that express β-lactamase. To do this, we employed a
prodrug strategy that utilized a β-lactam cleavable motif linked
to the broad-spectrum antibiotic ciproﬂoxacin.
In support of our approach, the use of β-lactams as prodrug
modiﬁers in antibody-directed enzyme prodrug therapy
approaches has been explored in disease areas such as cancer
(1−3, Figure 1).31−35 Additionally, β-lactam−ﬂuoroquinolone
conjugates have been proposed as a co-drug strategy to treat
bacterial infections (4 and 5, Figure 1).36−39 However, our
approach is diﬀerent in that it is designed to selectively deliver
a broad-spectrum, bactericidal antibiotic to only bacteria that
express β-lactamase, while having minimal eﬀect on bacteria
that do not express the resistance determinant. By contrast,
previous dual activity co-drug approaches were designed to
have broad-spectrum activity against both drug-sensitive
bacteria and those that express β-lactamase.
Herein we describe the design and development of the
prodrug, including optimization of the β-lactam motif to
reduce the antibacterial activity of the intact molecule and
increase the eﬃciency of β-lactamase mediated ciproﬂoxacin
release. This is, to our knowledge, the ﬁrst example of a β-
lactam-ﬂuoroquinolone prodrug with selective activity against
drug-resistant bacteria.
■ RESULTS AND DISCUSSION
Prodrug Design. In order to create a prodrug molecule
that is selectively activated in β-lactamase producing bacteria, it
was important to select a β-lactamase cleavable motif, linkage
strategy, and active antibiotic that gave a stable nonbactericidal
intact molecule and enabled the rapid and eﬃcient release of
the antibiotic upon activation by β-lactamase. The success of
this strategy required a prodrug motif that would enable
eﬃcient substrate turnover rather than inhibition of the β-
lactamase enzyme. The cephalosporin class of β-lactams are
eﬃciently hydrolyzed by β-lactamases and have been
previously employed as a prodrug motif as cleavage of the β-
lactam ring is associated with the loss of the functional group at
the 3′-position (Figure 2A).40 In addition, the chemistry
associated with changing the 3′-substituent of cephalosporins
is well-established and a wide variety of substituents at the C-3′
position are tolerated by β-lactamases.37,41,42 Consequently, a
cephalosporin core was selected as the β-lactam component.
To achieve the desired selectivity proﬁle, ciproﬂoxacin was
attached via the carboxylic acid to give the 3′-cephem ester 6
(Figure 2B). Derivatization of the carboxylic acid group of
ﬂuoroquinolone antibiotics is associated with a signiﬁcant
decrease in antibacterial activity due to a decreased ability to
bind to bacterial DNA−enzyme complexes.43 While this choice
of attachment site was selected to remove the ciproﬂoxacin
activity from the intact prodrug, it remained likely that the
Figure 1. Selected representative examples of cephalosporin prodrugs (PROTAX 1,33 2,34 and BMY-46633 335) and co-drugs (MCO 438 and Ro
23-9424 539).
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prodrug molecule would retain antibacterial activity as a result
of the ability of the cephem portion of the molecule to interact
with PBPs. Therefore, to further increase selectivity, it was
essential to undertake a program of optimization of the β-
lactam motif to reduce PBP activity and increase or maintain
β-lactamase activity. Initial optimization was performed on the
cephalosporin portion of the prodrug to enable the rapid
generation of analogues and evaluation of biological activity.
The cephalosporin analogues with the most desirable activity
proﬁle were then selected for preparation as the full prodrug.
β-Lactam Analogue Preparation and Biological
Evaluation. Analysis of the literature identiﬁed the amide
functionality at C-7 of the cephem ring as central to PBP and
β-lactamase activity,44−51 and therefore structural changes at
this position provided the initial focus of investigation. By use
of cephalothin 7 (Table 1) as the starting point, analogues
were prepared to explore bioisosteric replacement,52,53
functionalities present in early generation β-lactam antibiotics,
and to probe steric and electronic tolerance.54,55 All
compounds were synthesized according to the previously
reported methods (Figure S1 in Supporting Information).55,56
Antibacterial activity was assessed by determining the minimal
concentration required to inhibit bacterial growth, known as
the minimal inhibitory concentration (MIC), against the E. coli
strain DH5α ± expression of the ESBL TEM-116.57 The
susceptibility to β-lactamase mediated hydrolysis was assessed
by determining the physiological eﬃciency (kcat/Km) of
hydrolysis by recombinant AmpC protein.3,58,59
For all compounds (Table 1), a higher MIC value was
determined for the E. coli strain expressing TEM-116 than the
strain not expressing β-lactamase, indicating hydrolytic activity
by the β-lactamase. Introduction of a substituent to the
thiophene ring (8) or switching from a C-2 to a C-3
substitution (9) gave a modest increase in MIC values and a
small decrease in kcat/Km compared to cephalothin 7. Although
no measurable MIC value could be determined for any of the
phenyl analogues (20−23), this was accompanied by a >3-fold
decrease in kcat/Km. In general, a quaternary carbon (20−24)
or tertiary carbon (10 and 25) at the α-position relative to the
amide carbonyl was not well tolerated by AmpC. This ﬁnding
is consistent with prior reports and has previously been
exploited to reduce β-lactamase activity in the development of
later-generation β-lactams. Compounds containing straight-
chain aliphatic groups (26−28) retained some antibacterial
activity; an increase in kcat/Km was observed with increasing
chain length.
Examination of the tested analogues (Table 1) immediately
revealed the importance of bulky benzylic substituents (11−
19). Thiophene rings are frequently used as a bioisosteric
replacement for a phenyl groups, and it is therefore perhaps
unsurprising that there was only a modest 4-fold increase in
MIC value against E. coli DH5α and a slight decrease in kcat/
Km for 11 compared to cephalothin.
52,53 However, introduc-
tion of substituents at the para-position (12−17) gave a
further 2- to 4-fold increase in MIC against E. coli DH5α
compared to unsubstituted benzyl 11. Substitution at the para-
Figure 2. (A) Mechanism of β-lactamase triggered cephalothin
hydrolysis. (B) General structure of proposed cephalosporin−
ciproﬂoxacin prodrug 6.
Table 1. Antibacterial Activities (MIC) and AmpC
Hydrolytic Eﬃciency of Synthesized Compounds and
Reference Compound Cephalothin (Ceph) 7
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position also aﬀected hydrolysis by AmpC with the following
order of activity observed: F < Me = H < Cl = Br. Movement
of the methyl substituent from the para- (12) to the meta-
position (18) gave a 5-fold increase in kcat/Km and a 3-fold
increase compared to cephalothin. High kcat/Km values were
determined for bisaryl 16 and the para- and meta-substituted
biphenyl ethers 17 and 19 (3.99 ± 0.88, 7.33 ± 1.72, and
31.14 ± 2.67, respectively). In addition, no measurable MIC
values could be determined for 16, 17, or 19. This led us to
question if the results were indicative of no antibacterial
activity or simply a result of increased eﬄux activity out of, or a
lack of permeability into, the bacterial cell.
β-Lactamase Hydrolytic Activity in Whole-Cell NMR
Assay. To address the question of compound permeability/
eﬄux, a whole-cell β-lactamase hydrolysis assay was used to
detect the penetration of compounds into the periplasm.60,61
Hydrolytic decomposition of β-lactam rings is associated with
changes in 1H NMR signals, which can be detected using
whole bacterial cells in real time by 1H NMR spectroscopy
(Figure S2). As hydrolysis occurred within the bacterial
periplasm, only compounds with suﬃcient intracellular
accumulation were hydrolyzed. Compounds 16 and 17 were
selected as representative examples of high lipophilicity
compounds with no measurable antibacterial activity and
moderate in vitro β-lactamase hydrolysis. We evaluated the
hydrolysis of bisaryl 16, biaryl ether 17, and cephalothin 7 in
DH5α ± TEM-116 (Table 2). After 90 min, 16 was 69%
hydrolyzed in DH5α + TEM-116 compared to 14% hydro-
lyzed in DH5α − TEM-116 and 17 was 53% hydrolyzed in
DH5α + TEM-116 compared to 13% hydrolyzed in DH5α −
TEM-116. These results indicated a high degree of in vivo β-
lactamase mediated hydrolysis and that 16 and 17 accumulated
in the bacterial cell. We therefore concluded that the lack of
antibacterial activity of this compound against E. coli DH5α
without β-lactamase was due to an absence of PBP engagement
and not due to poor permeability or eﬄux activity.
Biological Evaluation in Uropathogenic E. coli. Initial
assessment of compound activity was performed in the
laboratory E. coli strain DH5α. To assess the activity of the
β-lactams against a clinically relevant pathogenic strain of E.
coli, we selected the uropathogenic strain CFT073. This
bacterium was isolated from the blood of a patient with acute
pyelonephritis, is devoid of all virulence plasmids commonly
associated with uropathogenic strains, and proved tractable for
genetic manipulation.62,63 The plasmid pSU18, without the
coding sequence for β-lactamase (referred to here as pEMP) or
encoding for the β-lactamase CTX-M-1, was introduced into
CFT073, enabling comparison of compound activity in
CFT073 and CFT073 + pSU18 ± β-lactamase. The primary
β-lactamase used in this work was CTX-M-1 because CTX-M
enzymes are the most prevalent β-lactamases among enter-
obacteria such as E. coli. As part of a class of extended-
spectrum β-lactamases (ESBL) it confers resistance to most β-
lactam antibiotics, with the exception of carbapenems.6
In the ﬁrst instance, MIC values were determined for
selected compounds against CFT073 + pSU18 ± CTX-M-1
(Table 3). For all the compounds tested, the MIC values for
CFT073 + pSU18 were within 2-fold of those determined
against DH5α. Next the hydrolytic activity of these compounds
was assessed in the whole cell NMR assay (Table 3). For the
majority of the compounds tested, a low level of hydrolysis,
<20% after 60 min, was detected. However, levels of hydrolysis
comparable to that observed for cephalothin (68%) were
observed only for 24 and 26 (64% and 67%, respectively).
A clear feature of the SAR was that CTX-M-1 mediated
hydrolytic activity in whole CFT073 cells correlated with
lipophilicity. Plotting the calculated log P (cLogP) values for
compounds against the log of percentage hydrolysis revealed
that moderate−high levels of hydrolysis (>30%) were only
observed for compounds with cLogP values below 0.1 (Figure
3). Linear regression analysis revealed moderate correlation
(R2 = 0.60), despite the degree of hydrolysis reﬂecting both
cellular penetration and β-lactamase activity, which are both
sensitive to compound lipophilicity.
Interestingly, compounds 16 and 17 were hydrolyzed rapidly
(69% and 54% after 90 min, respectively) in DH5α expressing
the TEM-116 β-lactamase (Table 2) but only 4% hydrolyzed
after 60 min in CFT073 expressing the CTX-M-1 β-lactamase.
We hypothesized that the low level of hydrolytic activity
observed for many of the compounds could be a result of poor
intracellular accumulation in CFT073 E. coli since clinical
isolates often have reduced permeability to antibiotics.64 To
test this hypothesis, hydrolysis in DH5α expressing CTX-M-1
was determined for cepaholothin 7, 16, and 17 (Table 2).
After 60 min complete hydrolysis for cepaholothin 7 and 16
and 94% hydrolysis for 17 were observed, suggesting that the
low level of hydrolysis observed in CFT073 + CTX-M-1 was
not due to the inability of CTX-M-1 to hydrolyze this
chemotype. Instead it is likely that due to poor membrane
permeability or increased eﬄux activity, lipophilic analogues
were unable to engage with CTX-M-1 in CFT073. For
compounds with low hydrolytic activity in the whole cell NMR
assay with CFT073 we were unable to discern if a high MIC
value in the absence of CTX-M-1 truly reﬂected a lack of
antibacterial activity or a lack of permeability/high eﬄux
activity. Therefore, compound 26, with its high MIC value in
both CFT073 ± CTX-M-1 (≥400 μM) and high hydrolytic
activity in whole CFT073 cells (67% after 60 min), was
selected for incorporation into the full prodrug molecule.
Compound 24, which also possessed a high MIC value in both
CFT073 ± CTX-M-1 (≥400 μM) and high hydrolytic activity
in whole CFT073 cells (64% after 60 min), was not progressed
at this time as we wished to avoid the potential for toxicity
problems arising from the furan ring, which has been identiﬁed
as common toxicophore due to metabolic instability.65
Prodrug Preparation. Preparation of the prodrug derived
from compound 26 required coupling of an activated 26
derivative, iodocephalosporin 30, to ciproﬂoxacin derivative 33
(Scheme 1). The iodocephalosporin 30 was prepared in three
steps from commercially available 7-aminocephalosporanic
Table 2. Percentage Hydrolysis of Cephalothin (Ceph) 7
and Compounds 16 and 17 by DH5α Cells ± β-Lactamase
in Whole-Cell NMR Hydrolysis Assay
% hydrolysis
by NMR
compd
concn
(μM)
incubation
time (min) strain −βla +βla
Ceph 7 50 60 DH5a ± TEM-116 61
16 100 90 14 69
17 100 90 13 53
Ceph 7 100 60 DH5a ± CTX-M-1 0 100
16 100 60 0 100
17 100 60 0 95
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acid (7-ACA). First, 7-ACA was reacted with acetic anhydride
to give N-acetyl 26.55 Protection of the carboxylic acid as the
tert-butyl ester was then performed using tert-butyl 2,2,2-
trichloroacetimidate (TBTA) enabling formation of the tert-
butyl ester 29 in the absence of base,66 which has previously
been reported to be associated with isomerization from the Δ3-
cephem to the biologically inactive Δ2-cephem.67−69 Iodina-
tion at the 3′-position with TMSI gave the activated
iodocephalosporin 30 ready for coupling.36 The ciproﬂoxacin
component was prepared by BOC protection of the piperazine
NH to give 32 and subsequent conversion of the carboxylic
acid to the sodium salt 33.70 Coupling of compounds 30 and
33 was performed in 3:1 1,4-dioxane/DMF to give the
protected cephalosporin−ciproﬂoxacin conjugate 34.36,67
Finally, global deprotection with TFA to remove the BOC
and tert-butyl ester aﬀorded the ﬁnal prodrug 35.71 Synthesis
of 35 was achieved in seven steps from commercially available
materials without the requirement for toxic metal reagents.
In Vitro DNA Gyrase Activity. Members of the
ﬂuoroquinolone antibiotic family, including ciproﬂoxacin 31,
target the type II topoisomerase enzymes, DNA gyrase, and
topoisomerase IV. Inhibition of these enzymes results in the
arrest of DNA replication and transcription preventing
bacterial cell growth.43,72 Having successfully prepared prodrug
35, we moved to testing our hypothesis that the intact prodrug
would not inhibit DNA gyrase or topoisomerase IV but β-
lactamase triggered hydrolysis would result in the release of
free ciproﬂoxacin capable of engaging these targets. To test this
hypothesis, we evaluated the ability of prodrug 35 and
ciproﬂoxacin to inhibit recombinant DNA gyrase enzyme
activity in the absence and presence of the puriﬁed
recombinant β-lactamase CTX-M-15 (Figure 4). Compounds
were incubated with relaxed pBR322 plasmid DNA with and
without recombinant CTX-M-15 and recombinant DNA
gyrase. As predicted, inhibition of DNA gyrase by prodrug
35 was not observed in the absence of CTX-M-15. However,
in the presence of CTX-M-15, 1 μM 35 was capable of
reducing DNA gyrase activity by >50%. Ciproﬂoxacin 31
activity was not aﬀected by CTX-M-15. These results
conﬁrmed that β-lactamase-speciﬁc hydrolysis of 35 results in
liberation of active antibiotic capable of DNA gyrase inhibition
in vitro.
Selective Prodrug Activity against Uropathogenic E.
coli Expressing β-Lactamase. Next, the activity of prodrug
35 was evaluated using whole bacterial cells. MIC values for 35
and ciproﬂoxacin 31 were determined in E. coli CFT073
expressing the disease-relevant β-lactamases CTX-M-1, New
Delhi metallo-β-lactamase 1 (NDM-1), and Klebsiella pneumo-
niae carbapenemase (KPC-3) β-lactamase (Figure 5). NDM-1
is an example of an increasingly prevalent β-lactamase that is
capable of hydrolyzing carbapenems, usually considered the
last line of defense against β-lactamase expressing bacteria,73
while KPC enzymes are class A β-lactamases and the most
common carbapenemases globally.74,75
As expected, the MIC value determined for ciproﬂoxacin
was consistent across all tested strains at 31 nM. The MIC
determined for prodrug 35 in E. coli CFT073 WT and
Table 3. Antibacterial Activities (MIC) against CFT073 ±
CTX-M-1 and Percentage Hydrolysis in CFT073 + CTX-M-
1 Cells for Selected Compounds and Reference Compound
Cephalothin (Ceph) 7b
aPercentage hydrolysis determined for 100 μM compound at 1 h by
whole-cell NMR assay. bND = not done.
Figure 3. Plot of log of percentage hydrolysis in CFT073 + CTX-M-1
cells against calculated log P (cLogP) for synthesized compounds
(ﬁlled circle) and cephalothin 7 (open circle): linear regression
(dashed line), R2 = 0.60 (GraphPad Prism 7).
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expressing empty plasmid (pEMP) was 310 nM, representing a
10-fold decrease in activity compared to ciproﬂoxacin 31 in the
absence of β-lactamase. By contrast to bacteria without β-
lactamase, the MIC value for 35 was 63 nM for E. coli CFT073
strains expressing CTX-M-1, NDM1, or KPC, only 2-fold
higher than ciproﬂoxacin 31. These data demonstrate eﬃcient
and selective β-lactamase mediated prodrug cleavage and active
antibiotic release, resulting in arrest of bacterial cell growth at
concentrations comparable to that with free ciproﬂoxacin.
The activity of prodrug 35 compared to ciproﬂoxacin was
proﬁled further in six independently isolated uropathogenic E.
coli clinical isolates expressing the CTX-M-15 β-lactamase,
which were obtained from Charing Cross Hospital, Imperial
College NHS Trust. Three of the strains were ciproﬂoxacin
sensitive (EC11, EC16, and EC17), and three were
ciproﬂoxacin resistant (EC12, EC13, and EC19) as determined
by diagnostic susceptibility testing. Activity of prodrug 35 was
conﬁrmed against the three ciproﬂoxacin sensitive bacterial
strains, while no arrest in bacterial growth was observed for
either ciproﬂoxacin 31 or prodrug 35 for strain EC12, EC13,
or EC19 (Figure 6 and Table S1). These results demonstrate
that the antibacterial activity of 35 observed in β-lactamase
expressing strains is mediated through liberated ciproﬂoxacin
and provide evidence for the clinical utility of 35. The gut
microbiota includes both Gram-negative bacteria such as E. coli
and Gram-positive organisms such as E. faecalis. Since we had
shown that 35 was inactive against E. coli, we decided to
further examine the potential clinical value of the prodrug by
testing its activity against two representative E. faecalis strains
that did not express β-lactamase. Prodrug 35 showed reduced
activity compared to ciproﬂoxacin, indicating that our
approach could minimize undesirable damage to the micro-
biota caused by ﬂuoroquinolones (Figure S3). We also
assessed the activity of 35 against CFT073 pEMP or pCTX-
M-1 in the presence of human serum, which can modulate
drug activity via protein-binding and also contains esterases
that have the potential to activate the prodrug by cleaving the
ester linkage. However, data from MIC assays performed in the
presence of human serum (Figure S4) were equivalent to those
obtained in the absence of serum (Figure 5). Combined, these
Scheme 1. Synthesis of Prodrug 35a
aReagents and conditions: (i) acetic anhydride, NaHCO3, H2O, acetone, 0 °C, 30 min; (ii) TBTA, DCM, 60 °C, 16 h; (iii) TMSI, DCM, rt, 2 h;
(iv) Boc2O, 1 M NaOH, THF, rt, 16 h; (v) 0.1 M NaOH, MeOH, rt, 30 min; (vi) 3:1 1,4-dioxane/DMF, rt, 4 h; (vii) 1:1 TFA/DCM, anisole, 0
°C to rt.
Figure 4. Activity of prodrug 35 and ciproﬂoxacin 31 against recombinant DNA gyrase ± CTX-M-15. (A) DNA was separated by agrose gel
electrophoresis with 2 log DNA ladder: oc, open circle DNA; rel, relaxed DNA; sc, supercoiled DNA. (B) Quantiﬁcation of gel bands
corresponding to supercoiled DNA and normalized to no gyrase and gyrase only activity (ImageJ 1.52a): Gyr, DNA gyrase; cip, ciproﬂoxacin 31;
PD, prodrug 35; CTX, CTX-M-15. Error bars represent SEM (n = 4); prodrug vs prodrug + CTX-M-15 was analyzed by unpaired t-test, p = 0.0004
(GraphPad Prism 7.03).
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ﬁndings provided further conﬁdence in the selectivity of
prodrug 35 and its stability in the host environment.
Selective Bactericidal Activity against β-Lactamase
Expressing Bacteria. Finally, the ability of prodrug 35 to kill
bacteria rather than arrest growth was evaluated. Survival of E.
coli CFT073 pEMP or pCTX-M-1 with no treatment or
exposed to ciproﬂoxacin 31 or prodrug 35 was determined
over time by CFU counts (Figure 7). After 6 h incubation with
prodrug 35 there was >100-fold greater killing of E. coli
expressing CTX-M-1, compared with bacteria that did not
express the enzyme. Killing activity of 35 in E. coli expressing
CTX-M-1 was almost identical to free ciproﬂoxacin, while
growth comparable to no treatment controls was detected for
CFT073 expressing empty plasmid incubated with 35. These
ﬁndings demonstrate that it is possible to selectively kill β-
lactamase-producing bacteria using our prodrug approach,
Figure 5. Antibacterial activities for prodrug 35 (blue) and ciproﬂoxacin 31 (red) against CFT073 E. coli cells WT and expressing empty plasmid
(pEMP), CTX-M-15 (pCTX), NDM1 (pNMD1), and KPC (pKPC): (A) dose−response curves, where each point represents the mean ± SEM, n
= 3; (B) summary of MIC values.
Figure 6. Eﬀect of prodrug 35 (blue) or ciproﬂoxacin 31 (red) against six uropathogenic E. coli clinical isolates. Each point represents the mean ±
SEM, n = 3.
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without adversely aﬀecting bacteria that do not produce β-
lactamase.
■ CONCLUSIONS
A novel cephalosporin−ﬂuoroquinolone antibiotic prodrug has
been designed, synthesized, and evaluated for biological
activity. A program of optimization was successfully under-
taken to reduce the antibacterial activity of the intact prodrug
though modiﬁcation to the cephalosporin component. Prodrug
35 exhibits similar growth inhibitory activity to ciproﬂoxacin
against uropathogenic E. coli expressing the diverse ESBLs
CTX-M-1, NDM-1, and KPC but little activity against strains
that did not express β-lactamases. The selectively observed for
bactericidal activity was even greater, with prodrug 35 killing β-
lactamase expressing bacteria at the same rate as free
ciproﬂoxacin while not aﬀecting the growth of bacteria that
did not express β-lactamases.
Overall, the activity of prodrug 35 is consistent with (1)
permeability to pathogenic Gram-negative bacteria, (2) a low-
level of antibacterial activity for the intact prodrug, (3) β-
lactamase mediated intracellular release of ciproﬂoxacin upon
cleavage of the cephalosporin, and (4) activation of the
prodrug by a broad range of β-lactamases.
Together, these studies demonstrate that our prodrug
approach can harness resistance as a therapeutic opportunity
to selectively kill antibiotic-resistant bacteria. Since ﬂuoroqui-
nolones are a clinically useful, broad-spectrum antibiotic, we
envisage that increasing the selectivity proﬁle will have two
major advantages. First, increased selectivity of ﬂuoroquino-
lones will enable maintenance of the microbiota leading to
reduced secondary infection rate and subsequent antibiotic
use. Second, there is a decreased side-eﬀect proﬁle due to
minimized exposure of host cells to ﬂuoroquinolone antibiotic.
The focus of this work was uropathogenic E. coli (UPEC),
which is a major cause of UTIs and frequently expresses β-
lactamase. Our approach is expected to result in high
concentrations of active ciproﬂoxacin at the site of infection
(bladder and kidneys), without causing disruption to the host
microbiota. However, it is important to consider that the
primary reservoir of UPEC is the gut, and it is envisaged that
our prodrug approach would also enable the selective
decolonization of ESBL-expressing E. coli from the GI tract
of people who suﬀer from recurrent UTI. An additional use
could be the treatment of lung infections caused by P.
aeruginosa in patients with cystic ﬁbrosis, for which
ﬂuoroquinolones are the only available oral antibiotics.76,77
Since >65% P. aeruginosa isolates express the AmpC β-
lactamase,78 it is possible that our prodrug approach could be
used treat the infection without the associated damage to the
microbiota.
In summary, this study paves the way for the development
and use of small molecule therapeutics that selectively target
drug-resistant pathogens using broad-spectrum antibiotics
while minimizing selection for resistance and without collateral
damage to the microbiota. This complements ongoing eﬀorts
to alter the spectrum of activity of existing antibiotics to enable
them to be used in new ways. For example, recent work from
Liu and co-workers79 described an approach to broaden the
spectrum of activity of the otherwise Gram-positive restricted
oxazolidinone antibiotics to confer activity against Gram-
negative bacteria. By contrast, our approach restricts the
activity of the normally broad-spectrum agent ciproﬂoxacin to
only those bacteria that express the β-lactamase resistance
determinant. We anticipate that the modiﬁcation of existing
antibiotics will prolong and expand their clinical utility, while
eﬀorts to discover new antibiotic classes are underway.
■ EXPERIMENTAL SECTION
Experimental Procedures (Chemistry). Unless otherwise
stated, reactions were conducted in oven-dried glassware under an
atmosphere of argon using anhydrous solvents. All commercially
obtained reagents and solvents were used as received. TLC analysis
was performed on precoated aluminum sheets of silica (60 F254 nm,
Merck) and visualized using short-wave UV light. Column
chromatography was also performed on an Isolera Spektra Four
puriﬁcation system using Biotage Flash silica cartridges (SNAP KPSil,
SNAP Ultra, or SNAP KP-C18-HS). 1H NMR spectra were recorded
on Bruker Av-400 spectrometers at 400 MHz using an internal
deuterium lock. Chemical shifts are quoted in parts per million (ppm)
using the following internal references: CDCl3 (δH 7.26), D2O (δH
4.79), and DMSO-d6 (δH 2.50). Signal multiplicities are recorded as
singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet
of doublets (dd), triplet of triplets (tt), apparent (app), broad (br), or
obscured (obs). Coupling constants, J, were measured to the nearest
0.1 Hz. 13C NMR spectra were recorded on Bruker Av-400
spectrometers at 101 MHz using an internal deuterium lock.
Chemical shifts are quoted to 0.1 ppm, unless greater accuracy was
required, using the following internal references: CDCl3 (δC 77.0) and
DMSO-d6 (δC 39.5). High resolution mass spectra were recorded on a
Waters LCT with a Waters Aquilty UPLC I-class system operating in
ES+ or ES− mode. Analytical separation was performed using a
Waters BEH Acquity C18, 50 mm × 2.1 mm column using a ﬂow rate
of 0.5 mL/min in a 4 min gradient elution at 40 °C. The mobile phase
was a mixture of 99.9% water and 0.1% formic acid (solvent A) and
99.9% acetonitrile and 0.1% formic acid (solvent B). Gradient elution
was as follows: 95:5 (A/B) to 5:95 (A/B) over 3.2 min and then
reversion back to 95:5 (A/B) over 0.3 min, ﬁnally 95:5 (A/B) for 0.5
min. For accurate mass determination, samples were referenced
against leucine enkaphalin or sulfadimethoxine. All tested compounds
were ≥95% pure by LCMS analysis. All ﬁnal compounds were
screened through computational PAINS and aggregator ﬁlters and
gave no structural alerts as potential assay interference compounds or
aggregators.80,81 All compounds were soluble at the concentrations
used for biological evaluation.
General Synthetic Procedures. Method A. 7-Aminocephalospor-
anic acid (1 equiv) was dissolved in sat. NaHCO3 (aq) and acetone
added, followed by acid chloride (1.2 or 2 equiv). The reaction was
stirred at room temperature for 30 min, then washed with EtOAc.
The aqueous layer was acidiﬁed to pH 2 with 1 M HCl and extracted
with DCM (×3).55 The organic extracts were combined, dried over
Na2SO4, evaporated and the resulting solid was triturated with ice-
cold Et2O (unless otherwise stated) to aﬀord the product.
Figure 7. Survival of CFT073 pEMP (open circle) and pCTX (ﬁlled
circle) with no treatment (green), ciproﬂoxacin 31 (78 nM) (red), or
prodrug 35 (78 nM) (blue): Cipro, ciproﬂoxacin; PD, prodrug 35.
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Method B. 7-Aminocephalosporanic acid (1 equiv) and acid
chloride (2 equiv) were dissolved in EtOAc and heated to reﬂux
for 30 min. After cooling to room temperature, aniline (1.3−3 equiv)
was added and stirred for 1 h before the reaction mixture was diluted
with 3% NaHCO3 (aq). The aqueous layer was separated and the
organic layer washed with 3% NaHCO3 (aq) (×2). The aqueous
layers were combined, washed with EtOAc, and acidiﬁed to pH 2 with
1 M HCl.55 The desired product was isolated as described.
Method C. Carboxylic acid (1 equiv) was dissolved in DCM and
oxalyl chloride (1.2 equiv) added followed by DMF (1 drop) and the
reaction stirred for 16 h.56 The solvent was removed under reduced
pressure to aﬀord the acyl chloride, which was used without further
puriﬁcation.
Preparation of Compounds. (6R,7R)-3-(Acetoxymethyl)-7-
(2-(4-bromothiophen-2-yl)acetamido)-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (8). 2-(4-Bromo-
thiophen-2-yl)acetic acid (203 mg, 0.92 mmol), N-(3-dimethylamino-
propyl)-N′-ethylcarbodiimide hydrochloride (193 mg, 1.01 mmol),
and 7-aminocephalosporanic acid (250 mg, 0.92 mmol) were
suspended in DMF (8 mL) and stirred at room temperature for 48
h.82 The resulting mixture was ﬁltered and the ﬁltrate diluted with
H2O and extracted with EtOAc (×3). The organic extracts were
combined, washed with 1 M LiCl (aq) and brine, and dried over
Na2SO4. Solvent was removed under reduced pressure and the
resulting oil triturated with Et2O. The precipitate was collected by
vacuum ﬁltration and washed with DCM to aﬀord the product as
beige amorphous solid (36 mg, 8%). IR (solid): υmax 3273, 3101,
2837, 1774, 1748, 1707, 1662, 1539, 1223 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ 9.15 (d, J = 8.1 Hz, 1H), 7.51 (d, J = 1.2 Hz, 1H), 6.93
(s, 1H), 5.68−5.59 (m, 1H), 5.06 (d, J = 4.8 Hz, 1H), 5.00 (d, J =
12.6 Hz, 1H), 4.70 (d, J = 12.6 Hz, 1H), 3.78 (d, J = 2.6 Hz, 2H),
3.58 (d, J = 18.0 Hz, 1H), 3.42 (d, J = 18.7 Hz, 1H), 2.02 (s, 3H). 13C
NMR (101 MHz, DMSO) δ 170.3, 169.4, 162.8, 139.1, 128.5, 122.8,
107.7, 59.0, 57.2, 35.6, 25.4, 20.6. HRMS (ESI+): calcd for
C16H17BrN2O6S2 (M + H)
+ 496.9453, found 496.9479.
(6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(thiophen-3-yl)-
acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
Acid (9). 3-Thiopheneacetic acid (104 mg, 0.74 mmol), oxalyl
chloride (76 μL, 0.88 mmol), and DMF (1 drop) were reacted in
DCM (3 mL) according to method C. The resulting acid chloride and
7-aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (100 μL) according to
method B. The aqueous layer was extracted with DCM (×3), and the
organic layers were combined, dried over Na2SO4, and evaporated.
The resulting solid was triturated with ice-cold DCM to aﬀord the
product as an oﬀ-white amorphous solid (48 mg, 33%). IR (solid):
υmax 3284, 1751, 1730, 1651, 1621, 1536, 1241 cm
−1. 1H NMR (400
MHz, DMSO-d6) δ 8.95 (d, J = 8.3 Hz, 1H), 7.46 (dd, J = 4.9, 3.0 Hz,
1H), 7.26 (dd, J = 2.9, 1.0 Hz, 1H), 7.03 (dd, J = 4.9, 1.2 Hz, 1H),
5.46 (dd, J = 8.3, 4.8 Hz, 1H), 4.99 (d, J = 11.9 Hz, 1H), 4.93 (d, J =
4.8 Hz, 1H), 4.73 (d, J = 11.9 Hz, 1H), 3.61−3.49 (m, 2H), 3.45 (d, J
= 17.2 Hz, 1H), 3.19 (d, J = 17.3 Hz, 1H), 2.00 (s, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 170.6, 170.5, 163.3, 162.8, 135.8, 135.6,
128.6, 125.7, 122.3, 64.7, 58.5, 57.2, 36.4, 25.1, 20.8. HRMS (ESI+):
calcd for C16H16N2O6S2 (M + H)
+ 397.0528, found 397.0540.
(6R ,7R ) -3-(Acetoxymethyl)-8-oxo-7-((R ) -2-phenyl-
propanamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbox-
ylic Acid (10). (R)-(−)-2-Phenylpropionic acid (101 μL, 0.74
mmol), oxalyl chloride (76 μL, 0.88 mmol), and DMF (1 drop) were
reacted in DCM (3 mL) according to method C. The resulting acid
chloride and 7-aminocephalosporanic acid (100 mg, 0.37 mmol) were
reacted in EtOAc (5 mL) prior to the addition of aniline (100 μL)
according to method B. The aqueous layer was extracted with DCM
(×3), and the organic layers were combined, dried over Na2SO4 and
evaporated. The resulting solid was triturated with ice-cold DCM to
aﬀord the product as a white amorphous solid (42 mg, 28%). IR
(solid): υmax 3571, 3317, 1785, 1759, 1718, 1662, 1517, 1238 cm
−1.
1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 8.4 Hz, 1H), 7.34−7.26
(m, 4H), 7.23−7.18 (m, 1H), 5.57 (dd, J = 8.4, 4.8 Hz, 1H), 4.99−
4.91 (m, 2H), 4.68 (d, J = 12.3 Hz, 1H), 3.82 (q, J = 7.1 Hz, 1H),
3.44 (d, J = 17.6 Hz, 1H), 3.24 (d, J = 17.7 Hz, 1H), 1.99 (s, 3H),
1.34 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 174.1,
170.3, 163.7, 163.1, 141.6, 128.1, 127.2, 126.6, 63.7, 58.5, 57.4, 44.2,
25.2, 20.7, 17.8. HRMS (ESI+): calcd for C24H24N2O6S (M + H)
+
405.1120, found 405.1131.
(6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-phenylacetamido)-5-
thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (11). 7-
Aminocephalosporanic acid (100 mg, 0.35 mmol) and phenylacetyl
chloride (97 μL, 0.73 mmol) were reacted in sat. NaHCO3(aq) (10
mL) and acetone (5 mL) according to method A to aﬀord the
product as a white amorphous solid (45 mg, 31%). IR (solid): υmax
3254, 3034, 1778, 1737, 1707, 1654, 1536, 1223 cm−1. 1H NMR (400
MHz, DMSO-d6) δ 13.71 (br s, 1H), 9.10 (d, J = 8.3 Hz, 1H), 7.35−
7.18 (m, 5H), 5.68 (dd, J = 8.3, 4.8 Hz, 1H), 5.08 (d, J = 4.8 Hz, 1H),
5.00 (d, J = 12.8 Hz, 1H), 4.68 (d, J = 12.8 Hz, 1H), 3.66−3.47 (m,
4H), 2.03 (s, 3H). 13C NMR (101 MHz, DMSO) δ 170.9, 170.2,
164.7, 162.8, 135.8, 129.0, 128.2, 126.54, 126.48, 123.1, 62.7, 59.1,
57.4, 41.6, 25.5, 20.6. HRMS (ESI+): calcd for C18H19N2O6S (M +
H)+ 391.0964, found 391.0972.
(6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(p-tolyl)acetamido)-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (12). 4-
Methylphenylacetic acid (111 mg, 0.74 mmol), oxalyl chloride (76
μL, 0.88 mmol), and DMF (1 drop) were reacted in DCM (3 mL)
according to method C. The resulting acid chloride and 7-
aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (100 μL) according to
method B. The resulting precipitate was collected by vacuum ﬁltration
and washed with DCM to aﬀord the product as a white amorphous
solid (63 mg, 42%). IR (solid): υmax 3261, 3045, 1778, 1752, 1707,
1655, 1536, 1223 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 13.66 (br
s, 1H), 9.04 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 8.1 Hz, 2H), 7.10 (d, J =
8.0 Hz, 2H), 5.67 (dd, J = 8.3, 4.8 Hz, 1H), 5.08 (d, J = 4.8 Hz, 1H),
5.00 (d, J = 12.8 Hz, 1H), 4.69 (d, J = 12.8 Hz, 1H), 3.62 (d, J = 18.1
Hz, 1H), 3.54−3.41 (m, 3H), 2.26 (s, 3H), 2.03 (s, 3H). 13C NMR
(101 MHz, DMSO) δ 171.1, 170.2, 164.8, 162.8, 135.5, 132.7, 128.9,
128.8, 62.7, 59.1, 57.4, 41.2, 25.5, 20.63, 20.57. HRMS (ESI+): calcd
for C19H21N2O6S (M + H)
+ 405.1120, found 405.1119.
(6R ,7R ) -3- (Acetoxymethyl) -7-(2-(4-ﬂuorophenyl) -
acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-car-
boxylic Acid (13). 4-Fluorophenylacetyl chloride (98 μL, 0.74
mmol) and 7-aminocephalosporanic acid (100 mg, 0.37 mmol) were
reacted in EtOAc (5 mL) prior to the addition of aniline (100 μL)
according to method B. The resulting mixture was cooled to 4 °C and
the precipitate collected by vacuum ﬁltration and washed with ice-
cold DCM to aﬀord the product as a white amorphous solid (61 mg,
41%). IR (solid): υmax 3273, 1763, 1736, 1659, 1532, 1215 cm
−1. 1H
NMR (400 MHz, DMSO-d6) δ 13.67 (br s, 1H), 9.10 (d, J = 8.2 Hz,
1H), 7.30 (dd, J = 8.4, 5.6 Hz, 2H), 7.12 (app t, J = 8.8 Hz, 2H), 5.67
(dd, J = 8.1, 4.8 Hz, 1H), 5.08 (d, J = 4.8 Hz, 1H), 5.00 (d, J = 12.8
Hz, 1H), 4.69 (d, J = 12.8 Hz, 1H), 3.65−3.46 (m, 4H), 2.03 (s, 3H).
13C NMR (101 MHz, DMSO-d6) δ 170.8, 170.1, 164.6, 162.8, 131.9,
130.9, 130.8, 126.4, 123.3, 115.0, 114.8, 62.7, 59.1, 57.4, 40.6, 25.5,
20.5. HRMS (ESI+): calcd for C18H18FN2O6S (M + H)
+ 409.0870,
found 409.0864.
(6R ,7R ) -3-(Acetoxymethyl)-7-(2-(4-chlorophenyl)-
acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-car-
boxylic Acid (14). Hexanoyl chloride (139 mg, 0.74 mmol) and 7-
aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (75 μL) according to
method B. The resulting precipitate was collected by vacuum ﬁltration
and washed with ice-cold DCM to aﬀord the product as a cream
amorphous solid (104 mg, 67%). IR (solid): υmax 3265, 3056, 1778,
1748, 1707, 1643, 1536, 1223 cm−1. 1H NMR (400 MHz, DMSO-d6)
δ 13.69 (br s, 1H), 9.13 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 8.5 Hz, 2H),
7.29 (d, J = 8.5 Hz, 2H), 5.67 (dd, J = 8.2, 4.8 Hz, 1H), 5.08 (d, J =
4.8 Hz, 1H), 5.00 (d, J = 12.8 Hz, 1H), 4.68 (d, J = 12.8 Hz, 1H),
3.65−3.45 (m, 4H), 2.03 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ
170.6, 170.2, 164.6, 162.8, 134.8, 131.3, 130.9, 128.2, 62.7, 59.1, 57.4,
40.8, 25.5, 20.6. HRMS (ESI+): calcd for C18H18ClN2O6S (M + H)
+
447.0394, found 447.0414.
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(6R ,7R )-3-(Acetoxymethyl)-7-(2-(4-bromophenyl)-
acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-car-
boxylic Acid (15). 3-Bromophenylacetyl chloride (171 mg, 0.74
mmol) and 7-aminocephalosporanic acid (100 mg, 0.37 mmol) were
reacted in EtOAc (5 mL) prior to the addition of aniline (75 μL)
according to method B. The resulting precipitate was collected by
vacuum ﬁltration and washed with ice-cold DCM to aﬀord the
product as a cream amorphous solid (131 mg, 76%). IR (solid): υmax
3265, 3060, 1782, 1748, 1707, 1651, 1543, 1223 cm−1. 1H NMR (400
MHz, DMSO-d6) δ 13.66 (br s, 1H), 9.14 (d, J = 8.2 Hz, 1H), 7.50
(d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 5.67 (dd, J = 8.2, 4.8 Hz,
1H), 5.08 (d, J = 4.8 Hz, 1H), 5.00 (d, J = 12.8 Hz, 1H), 4.68 (d, J =
12.8 Hz, 1H), 3.65−3.45 (m, 4H), 2.03 (s, 3H). 13C NMR (101
MHz, DMSO-d6) δ 170.6, 170.2, 164.7, 162.8, 135.2, 131.3, 131.1,
126.3, 123.4, 119.7, 62.7, 59.1, 57.4, 40.8, 25.5, 20.6. HRMS (ESI+):
calcd for C18H18BrN2O6S (M + H)
+ 469.0069, found 469.0076.
(6R,7R)-7-(2-([1,1′-Biphenyl]-4-yl)acetamido)-3-(acetoxy-
methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbox-
ylic Acid (16). 4-Biphenylacetic acid (156 mg, 0.736 mmol), oxalyl
chloride (76 μL, 0.88 mmol), and DMF (1 drop) were reacted in
DCM (3 mL) according to method C. The resulting acid chloride and
7-aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (100 μL) according to
method B. The resulting precipitate was collected by vacuum ﬁltration
and washed with ice-cold Et2O to aﬀord the product as a white
amorphous solid (112 mg, 65%). IR (solid): υmax 3302, 1756, 1737,
1654, 1621, 1536, 1237 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.02
(d, J = 8.3 Hz, 1H), 7.65 (d, J = 7.2 Hz, 2H), 7.60 (d, J = 8.2 Hz, 2H),
7.45 (app t, J = 7.6 Hz, 2H), 7.41−7.30 (m, 3H), 5.48 (dd, J = 8.3, 4.8
Hz, 1H), 5.00 (d, J = 11.9 Hz, 1H), 4.94 (d, J = 4.8 Hz, 1H), 4.75 (d,
J = 12.0 Hz, 1H), 3.62 (d, J = 13.9 Hz, 1H), 3.54 (d, J = 13.9 Hz, 1H),
3.46 (d, J = 17.2 Hz, 1H), 3.20 (d, J = 17.2 Hz, 1H), 2.00 (s, 3H). 13C
NMR (101 MHz, DMSO-d6) δ 170.9, 170.4, 163.4, 162.8, 139.9,
138.3, 135.7, 135.2, 129.6, 128.8, 127.2, 126.5, 126.5, 64.7, 58.5, 57.2,
41.2, 25.1, 20.7. HRMS (ESI+): calcd for C24H23N2O6S (M + H)
+
467.1277, found 467.1287.
(6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-phenoxyphenyl)-
acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
Acid (17). 4-Phenoxyphenylacetic acid (170 mg, 0.74 mmol), oxalyl
chloride (76 μL, 0.88 mmol), and DMF (1 drop) were reacted in
DCM (3 mL) according to method C. The resulting acid chloride and
7-aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (75 μL) according to
method B. The aqueous layer was extracted with DCM (×3), and the
organic layers were combined, dried over Na2SO4, and evaporated.
The resulting solid was precipitated from hot DCM to aﬀord the
product as a cream amorphous solid (24 mg, 14%). IR (solid): υmax
3280, 1774, 1730, 1655, 1532, 1223 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ 9.05 (d, J = 8.3 Hz, 1H), 7.37 (app t, J = 7.9 Hz, 2H),
7.29 (d, J = 8.5 Hz, 2H), 7.12 (t, J = 7.4 Hz, 1H), 7.04−6.89 (m, 5H),
5.57 (dd, J = 8.2, 4.8 Hz, 1H), 5.03−4.95 (m, 2H), 4.72 (d, J = 12.4
Hz, 1H), 3.59−3.46 (m, 3H), 3.33 (d, J = 17.7 Hz, 1H), 2.01 (s, 3H).
13C NMR (101 MHz, DMSO-d6) δ 171.0, 170.3, 163.7, 163.2, 156.9,
155.2, 131.0, 130.6, 130.0, 123.2, 118.6, 118.3, 63.7, 58.8, 57.3, 40.7,
25.3, 20.6. HRMS (ESI+): calcd for C24H23N2O7S (M + H)
+
483.1226, found 483.1212.
(6R,7R)-3-(acetoxymethyl)-8-oxo-7-(2-(m-tolyl)acetamido)-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (18). 3-
Methylphenylacetic acid (111 mg, 0.74 mmol), oxalyl chloride (76
μL, 0.88 mmol), and DMF (1 drop) were reacted in DCM (3 mL)
according to method C. The resulting acid chloride and 7-
aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (75 μL) according to
method B. The aqueous layer was extracted with DCM (×3), and the
organic layers were combined, dried over Na2SO4, and evaporated.
The resulting solid was triturated with DCM to aﬀord the product as
a cream amorphous solid (36 mg, 24%). IR (solid): υmax 3288, 1726,
1662, 1625, 1526, 1223 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 9.00
(d, J = 8.3 Hz, 1H), 7.17 (app t, J = 7.5 Hz, 1H), 7.12−6.98 (m, 3H),
5.51 (dd, J = 8.1, 4.7 Hz, 1H), 5.05−4.91 (m, 2H), 4.74 (d, J = 12.1
Hz, 1H), 3.56−3.41 (m, 3H), 3.26 (d, J = 17.5 Hz, 1H), 2.27 (s, 3H),
2.01 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.0, 170.5, 163.5,
163.3, 137.2, 135.8, 129.7, 128.1, 127.1, 126.1, 64.3, 58.6, 57.3, 41.5,
25.2, 21.0, 20.7. HRMS (ESI+): calcd for C19H21N2O6S (M + H)
+
405.1120, found 405.1126.
(6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(3-phenoxyphenyl)-
acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
Acid (19). 3-Phenoxyphenylacetic acid (170 mg, 0.74 mmol), oxalyl
chloride (76 μL, 0.88 mmol), and DMF (1 drop) were reacted in
DCM (3 mL) according to method C. The resulting acid chloride and
7-aminocephalosporanic acid (100 mg, 0.37 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (75 μL) according to
method B. The aqueous layer was extracted with DCM (×3), and the
organic layers were combined, dried over Na2SO4, and evaporated.
The resulting solid was precipitated from hot DCM to aﬀord the
product as a cream amorphous solid (22 mg, 12%). IR (solid): υmax
3280, 3042, 1771, 1726, 1659, 1528, 1226 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ 9.04 (d, J = 8.2 Hz, 1H), 7.39 (app t, J = 7.9 Hz, 2H),
7.31 (t, J = 7.9 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 7.07−6.95 (m, 4H),
6.87 (dd, J = 8.1, 2.2 Hz, 1H), 5.55 (dd, J = 8.1, 4.8 Hz, 1H), 5.02−
4.94 (m, 2H), 4.71 (d, J = 12.3 Hz, 1H), 3.59−3.45 (m, 3H), 3.30 (d,
J = 17.7 Hz, 1H), 2.01 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ
170.6, 170.3, 163.6, 163.1, 156.6, 156.5, 138.0, 130.0, 129.69, 124.2,
123.3, 119.2, 118.6, 116.7, 63.7, 58.8, 57.2, 41.4, 25.3, 20.6. HRMS
(ESI+): calcd for C24H23N2O7S (M + H)
+ 483.1226, found 483.1233.
(6R,7R)-3-(Acetoxymethyl)-7-benzamido-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (20). 7-Amino-
cephalosporanic acid (100 mg, 0.37 mmol) and benzoyl chloride
(51 μL, 0.44 mmol) were reacted in sat. NaHCO3 (aq) (10 mL) and
acetone (5 mL) according to method A to aﬀord the product as a
white amorphous solid (75 mg, 55%). IR (solid): υmax 3250, 1774,
1752, 1710, 1651, 1520, 1223 cm−1. 1H NMR (400 MHz, DMSO-d6)
δ 13.69 (br s, 1H), 9.41 (d, J = 8.0 Hz, 1H), 7.91 (d, J = 7.7 Hz, 2H),
7.57 (t, J = 7.3 Hz, 1H), 7.48 (app t, J = 7.5 Hz, 2H), 5.88 (dd, J =
8.1, 4.8 Hz, 1H), 5.19 (d, J = 4.8 Hz, 1H), 4.99 (d, J = 12.8 Hz, 1H),
4.70 (d, J = 12.7 Hz, 1H), 3.64 (d, J = 18.0 Hz, 1H), 3.50 (d, J = 18.0
Hz, 1H), 2.03 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.2,
166.9, 164.0, 162.8, 133.0, 131.8, 128.3, 127.7, 123.1, 62.7, 59.8, 57.6,
25.5, 20.5. HRMS (ESI+): calcd for C17H17N2O6S (M + H)
+
377.0807, found 377.0807.
(6R,7R)-3-(Acetoxymethyl)-7-(4-methylbenzamido)-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (21). 7-
Aminocephalosporanic acid (100 mg, 0.37 mmol) and 4-methyl-
benzoyl chloride (97 μL, 0.74 mmol) were reacted in sat. NaHCO3
(aq) (10 mL) and acetone (5 mL) according to method A to aﬀord
the product as a white amorphous solid (39 mg, 26%). IR (solid):
υmax 3258, 1774, 1730, 1648, 1525, 1223 cm
−1. 1H NMR (400 MHz,
DMSO-d6) δ 9.29 (d, J = 8.1 Hz, 1H), 7.83 (d, J = 7.8 Hz, 2H), 7.29
(d, J = 7.9 Hz, 2H), 5.81 (dd, J = 8.1, 4.7 Hz, 1H), 5.14 (d, J = 4.8 Hz,
1H), 4.99 (d, J = 12.5 Hz, 1H), 4.72 (d, J = 12.5 Hz, 1H), 3.59 (d, J =
17.7 Hz, 1H), 3.43 (d, J = 17.7 Hz, 1H), 2.37 (s, 3H), 2.03 (s, 3H).
13C NMR (101 MHz, DMSO) δ 170.3, 166.8, 163.5, 163.0, 141.8,
130.3, 128.8, 127.8, 63.4, 59.5, 57.6, 25.4, 21.0, 20.6. HRMS (ESI+):
calcd for C18H19N2O6S (M + H)
+ 391.0964, found 391.0972.
(6R,7R)-3-(Acetoxymethyl)-7-(4-methoxybenzamido)-8-
oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(22). 7-Aminocephalosporanic acid (100 mg, 0.37 mmol) and 4-
methoxybenzoyl chloride (100 μL, 0.74 mmol) were reacted in
EtOAc (5 mL) prior to the addition of aniline (100 μL) according to
method B. The aqueous layer was extracted with DCM (×3), and the
organic layers were combined, dried over Na2SO4, and evaporated.
The resulting solid was triturated with ice-cold Et2O to aﬀord the
product as a white amorphous solid (36 mg, 24%). IR (solid): υmax
3254, 1774, 1752, 1705, 1640, 1528, 1223 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ 9.22 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 8.9 Hz, 2H), 7.01
(d, J = 8.9 Hz, 2H), 5.84 (dd, J = 8.1, 4.8 Hz, 1H), 5.16 (d, J = 4.8 Hz,
1H), 4.98 (d, J = 12.7 Hz, 1H), 4.70 (d, J = 12.7 Hz, 1H), 3.82 (s,
3H), 3.62 (d, J = 17.9 Hz, 1H), 3.46 (d, J = 17.9 Hz, 1H), 2.03 (s,
3H). 13C NMR (101 MHz, DMSO-d6) δ 170.2, 166.3, 164.1, 162.9,
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162.1, 129.7, 125.1, 113.6, 62.9, 59.7, 57.7, 55.4, 25.5, 20.6. HRMS
(ESI+): calcd for C18H19N2O7S (M + H)
+ 407.0913, found 407.0919.
(6R,7R)-3-(Acetoxymethyl)-7-(4-nitrobenzamido)-8-oxo-5-
thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (23). 7-
Aminocephalosporanic acid (100 mg, 0.37 mmol) and 4-nitrobenzoyl
chloride (136 mg, 0.74 mmol) were reacted in sat. NaHCO3 (aq) (10
mL) and acetone (5 mL) according to method A. Several drops of
MeOH were added prior to the addition of ice-cold Et2O to aﬀord the
product as a white amorphous solid (54 mg, 35%). IR (solid): υmax
3265, 3064, 2971, 1785, 1748, 1711, 1640, 1595, 1524, 1223 cm−1.
1H NMR (400 MHz, DMSO-d6) δ 13.72 (s, 1H), 9.80 (d, J = 7.8 Hz,
1H), 8.34 (d, J = 8.8 Hz, 2H), 8.13 (d, J = 8.8 Hz, 2H), 5.88 (dd, J =
7.8, 4.7 Hz, 1H), 5.22 (d, J = 4.8 Hz, 1H), 5.00 (d, J = 12.8 Hz, 1H),
4.71 (d, J = 12.8 Hz, 1H), 3.66 (d, J = 17.9 Hz, 1H), 3.51 (d, J = 18.0
Hz, 1H), 2.03 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.7,
166.0, 164.0, 163.3, 149.9, 139.0, 129.8, 124.1, 63.2, 60.4, 58.0, 26.0,
21.0, 15.6. HRMS (ESI+): calcd for C17H16N3O8S (M + H)
+
422.0658, found 422.0660.
(6R,7R)-3-(Acetoxymethyl)-7-(furan-2-carboxamido)-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (24). 7-
Aminocephalosporanic acid (100 mg, 0.37 mmol) and 2-furoyl
chloride (73 μL, 0.74 mmol) were reacted in sat. NaHCO3 (aq) (10
mL) and acetone (5 mL) according to method A to aﬀord the
product as a white amorphous solid (30 mg, 22%). IR (solid): υmax
3243, 1793, 1718, 1710, 1632, 1595, 1223 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ 13.71 (br s, 1H), 9.29 (d, J = 8.2 Hz, 1H), 7.90 (d, J =
1.7 Hz, 1H), 7.36 (d, J = 3.5 Hz, 1H), 6.65 (dd, J = 3.5, 1.7 Hz, 1H),
5.81 (dd, J = 8.2, 4.8 Hz, 1H), 5.16 (d, J = 4.8 Hz, 1H), 4.99 (d, J =
12.8 Hz, 1H), 4.70 (d, J = 12.8 Hz, 1H), 3.64 (d, J = 18.0 Hz, 1H),
3.50 (d, J = 18.0 Hz, 1H), 2.03 (s, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 170.7, 164.4, 163.3, 158.4, 146.8, 146.5, 115.4, 112.4,
63.2, 59.6, 58.1, 26.0, 21.0. HRMS (ESI+): calcd for C15H15N2O7S (M
+ H)+ 367.0600, found 367.0609.
(6R,7R)-3-(Acetoxymethyl)-7-(cyclohexanecarboxamido)-8-
oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(25). 7-Aminocephalosporanic acid (100 mg, 0.37 mmol) and
cyclohexanecarbonyl chloride (60 μL, 0.44 mmol) were reacted in
sat. NaHCO3(aq) (10 mL) and acetone (5 mL) according to method
A to aﬀord the product as a white amorphous solid (15 mg, 11%). IR
(solid): υmax 3261, 2926, 2851, 1778, 1737, 1711, 1648, 1532, 1215
cm−1. 1H NMR (400 MHz, DMSO-d6) δ 13.67 (br s, 1H), 8.71 (d, J
= 8.2 Hz, 1H), 5.63 (dd, J = 8.2, 4.8 Hz, 1H), 5.07 (d, J = 4.8 Hz,
1H), 4.99 (d, J = 12.8 Hz, 1H), 4.67 (d, J = 12.8 Hz, 1H), 3.61 (d, J =
18.1 Hz, 1H), 3.46 (d, J = 18.0 Hz, 1H), 2.34−2.24 (m, 1H), 2.03 (s,
3H), 1.76−1.57 (m, 5H), 1.39−1.14 (m, 5H). 13C NMR (101 MHz,
DMSO) δ 176.1, 170.2, 164.8, 162.9, 62.8, 59.0, 57.6, 43.3, 29.8, 28.6,
25.4, 25.4, 25.2, 25.0, 20.6. HRMS (ESI+): calcd for C17H23N2O6S (M
+ H)+ 383.1277, found 383.1264.
(6R,7R)-7-Acetamido-3-(acetoxymethyl)-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (26). 7-Amino-
cephalosporanic acid (500 mg, 1.84 mmol) was suspended in H2O
(8 mL), NaHCO3 (387 mg, 4.60 mmol) was added and the resulting
mixture stirred at room temperature for 10 min before being cooled to
0 °C. Acetic anhydride (347 μL, 0.368 mmol) in acetone (10 mL)
was added and the reaction stirred at 0 °C for 30 min. Acetone was
removed under reduced pressure, and the resulting material was
diluted in H2O and neutralized with sat. NaHCO3 (aq). The aqueous
solution was washed with EtOAc, acidiﬁed to pH 2 with 1 M HCl and
extracted with EtOAc (×3). The organic layers were combined,
washed with brine, dried over Na2SO4, and evaporated to aﬀord the
product as a colorless foam (471 mg, 81%). IR (solid): υmax 3317,
2937, 1771, 1718, 1755, 1625, 1528, 1219 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ 13.67 (br s, 1H), 8.84 (d, J = 8.4 Hz, 1H), 5.68 (dd, J =
8.3, 4.9 Hz, 1H), 5.08 (d, J = 4.9 Hz, 1H), 5.00 (d, J = 12.8 Hz, 1H),
4.68 (d, J = 12.8 Hz, 1H), 3.63 (d, J = 18.0 Hz, 1H), 3.48 (d, J = 18.1
Hz, 1H), 2.03 (s, 3H), 1.91 (s, 3H). 13C NMR (101 MHz, DMSO) δ
170.2, 170.1, 165.0, 162.9, 126.4, 123.4, 62.7, 59.0, 57.4, 22.1, 20.6.
HRMS (ESI+): calcd for C12H15N2O6S (M + Na)
+ 337.0470, found
337.0479.
(6R,7R)-3-(Acetoxymethyl)-7-butyramido-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (27). Butyryl
chloride (76 μL, 0.74 mmol) and 7-aminocephalosporanic acid
(100 mg, 0.37 mmol) were reacted in EtOAc (5 mL) prior to the
addition of aniline (100 μL) according to method B. The aqueous
layer was extracted with DCM (×3), and the organic layers were
combined, dried over Na2SO4, and evaporated. The resulting solid
was triturated with ice-cold DCM to aﬀord the product as a white
amorphous solid (15 mg, 12%). IR (solid): υmax 3265, 2960, 1774,
1751, 1715, 1654, 1539, 1223 cm−1. 1H NMR (400 MHz, DMSO-d6)
δ 8.74 (d, J = 8.2 Hz, 1H), 5.61 (dd, J = 7.9, 4.8 Hz, 1H), 5.04 (d, J =
4.7 Hz, 1H), 4.99 (d, J = 12.6 Hz, 1H), 4.69 (d, J = 12.6 Hz, 1H),
3.57 (d, J = 17.8 Hz, 1H), 3.39 (d, J = 17.7 Hz, 1H), 2.21−2.13 (m,
2H), 2.02 (s, 3H), 1.52 (app h, J = 7.2 Hz, 2H), 0.86 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, DMSO) δ 172.9, 170.3, 164.4, 163.1,
63.3, 58.9, 57.4, 36.6, 25.4, 20.6, 18.7, 13.5. HRMS (ESI+): calcd for
C14H19N2O6S (M + H)
+ 343.0964, found 343.0959.
(6R,7R)-3-(Acetoxymethyl)-7-hexanamido-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (28). Hexanoyl
chloride (103 μL, 0.74 mmol) and 7-aminocephalosporanic acid
(100 mg, 0.37 mmol) were reacted in EtOAc (5 mL) prior to the
addition of aniline (100 μL) according to method B. The resulting
precipitate was collected by vacuum ﬁltration and washed with ice-
cold DCM to aﬀord the product as a white amorphous solid (78 mg,
57%). IR (solid): υmax 3283, 3183 2930, 1774, 1752, 1711, 1651,
1536, 1223 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 13.65 (br s,
1H), 8.78 (d, J = 8.2 Hz, 1H), 5.67 (dd, J = 8.2, 4.8 Hz, 1H), 5.08 (d,
J = 4.8 Hz, 1H), 4.99 (d, J = 12.8 Hz, 1H), 4.68 (d, J = 12.8 Hz, 1H),
3.62 (d, J = 18.1 Hz, 1H), 3.48 (d, J = 18.1 Hz, 1H), 2.23−2.13 (m,
2H), 2.03 (s, 3H), 1.56−1.46 (m, 2H), 1.32−1.18 (m, 4H), 0.86 (t, J
= 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 173.0, 170.1,
164.9, 162.8, 126.4, 123.2, 62.7, 59.0, 57.5, 34.6, 30.7, 25.5, 24.8, 21.8,
20.5, 13.8. HRMS (ESI+): calcd for C16H23N2O6S (M + H)
+
371.1277, found 371.1290.
tert-Butyl (6R,7R)-7-Acetamido-3-(acetoxymethyl)-8-oxo-5-
thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (29). Com-
pound 26 (75 mg, 0.24 mmol) was dissolved in DCM (2 mL), tert-
butyl 2,2,2-trichloroacetimidate (170 μL, 0.96 mmol) was added, and
the reaction was heated to 60 °C for 24 h. After cooling to room
temperature the reaction was diluted with MeOH. Solvent was
removed under reduced pressure and the resulting solid triturated
with cold DCM. The solute was loaded directly onto a 10 g SNAP
KPSil column and puriﬁed by column chromatography (0−10%
MeOH in DCM) to aﬀord the product as a cream glassy solid (82 mg,
93%). IR (thin ﬁlm): υmax 3291, 2982, 1774, 1718, 1670, 1528, 1368,
1223 cm−1. 1H NMR (400 MHz, CDCl3) δ 6.39 (d, J = 9.0 Hz, 1H),
5.84 (dd, J = 9.0, 4.9 Hz, 1H), 5.09 (d, J = 13.3 Hz, 1H), 4.95 (d, J =
4.9 Hz, 1H), 4.80 (d, J = 13.2 Hz, 1H), 3.55 (d, J = 18.4 Hz, 1H),
3.36 (d, J = 18.4 Hz, 1H), 2.08 (s, 3H), 2.06 (s, 3H), 1.53 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 170.7, 170.4, 164.9, 160.5, 127.5,
123.8, 84.0, 63.3, 59.4, 57.5, 27.9, 26.6, 23.0, 20.9. HRMS (ESI+):
calcd for C16H23N2O6S (M + H)
+ 371.1277, found 371.1276.
7-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-
ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (32). Ci-
proﬂoxacin 31 (500 mg, 1.51 mmol) was dissolved in 1 M NaOH
(aq) (5 mL) and THF (10 mL) added, followed by the dropwise
addition of Boc2O (360 mg, 1.66 mmol) in THF (10 mL) and stirred
at room temperature for 16 h. Solvent was removed under reduced
pressure and the resulting material diluted in H2O and neutralized
with sat. NH4Cl (aq). The precipitate was collected by vacuum
ﬁltration and washed with H2O to aﬀord the product as a white
amorphous solid (502 mg, 77%). IR (solid): υmax 2971, 1733, 1688,
1629, 1249 cm−1. 1H NMR (400 MHz, CDCl3) δ 14.95 (s, 1H), 8.78
(s, 1H), 8.05 (d, J = 12.9 Hz, 1H), 7.37 (d, J = 7.1 Hz, 1H), 3.73−
3.62 (m, 4H), 3.53 (tt, J = 7.3, 4.0 Hz, 1H), 3.34−3.25 (m, 4H), 1.50
(s, 9H), 1.43−1.37 (m, 2H), 1.24−1.17 (m, 2H). 13C NMR (101
MHz, CDCl3) δ 167.1, 154.7, 153.1, 147.7, 113.0, 112.7, 108.5, 105.1,
80.5, 35.4, 28.6, 8.4. HRMS (ESI+): calcd for C22H27N3O5F (M+H)
+
432.1935, found 432.1951.
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Sodium 7-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-1-cyclo-
propyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
(33). Compound 32 (105 mg, 0.240 mmol) was suspended in MeOH
(2.44 mL), 0.1 M NaOH (aq) (2.44 mL) was added, and the reaction
mixture was stirred at 30 °C for 30 min. Solvent was removed under
reduced pressure and resulting material suspended in H2O (5 μL) and
EtOH (5 mL) and evaporated to dryness (×3). Then, the solid was
suspended in DCM and evaporated to aﬀord the product as a cream
amorphous solid (111 mg, quant.). IR (solid): υmax 1617, 1478, 1242
cm−1.
t e r t -Buty l (6R , 7R ) - 7 -Ace tamido-3 - ( ( (7 - (4 - ( t e r t -
butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-ﬂuoro-4-oxo-
1,4-dihydroquinoline-3-carbonyl)oxy)methyl)-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylate (34). Compound 29
(198 mg, 0.54 mmol) was dissolved in DCM (8 mL) and TMSI (117
μL, 0.82 mmol) added dropwise.83 The reaction mixture was stirred
in the dark for 2 h at room temperature, then diluted with DCM and
washed with 10% (wt/v) Na2SO3 (aq). The organic layer was dried
over Na2SO4 and evaporated to a give compound 30 as a yellow glassy
solid. Compound 30 (120 mg, 0.27 mmol) and compound 33 (100
mg, 0.26 mmol) were suspended in anhydrous 1,4-dioxane (3.5 mL),
and DMF (1.15 mL) was added dropwise. The reaction mixture was
stirred in the dark for 2 h before the solvent was removed under a
stream of N2. The resulting material was dissolved in minimal DCM
and loaded directly onto a 10 g SNAP Ultra cartridge and puriﬁed by
column chromatography (0−6% MeOH in DCM) to aﬀord the
product as a pale yellow glassy solid (108 mg, 52%). IR (solid): υmax
2974, 1782, 1685, 1618, 1250 cm−1. 1H NMR (400 MHz, DMSO-d6)
δ 8.86 (d, J = 8.5 Hz, 1H), 8.44 (s, 1H), 7.80 (d, J = 13.3 Hz, 1H),
7.47 (d, J = 7.4 Hz, 1H), 5.71 (dd, J = 8.4, 4.9 Hz, 1H), 5.15−5.09
(m, 2H), 4.86 (d, J = 13.1 Hz, 1H), 3.72−3.62 (m, 3H), 3.58−3.50
(m, 4H), 3.25−3.16 (m, 4H), 1.91 (s, 3H), 1.49 (s, 9H), 1.43 (s, 9H),
1.31−1.25 (m, 2H), 1.13−1.05 (m, 2H). 13C NMR (101 MHz,
DMSO-d6) δ 171.5, 170.0, 164.9, 164.2, 160.5, 153.7, 152.6 (d,
1JC−F
= 247.5 Hz), 148.4, 143.8 (d, 2JC−F = 10.1 Hz), 138.0, 126.2, 123.5,
122.1 (d, 3JC−F = 7.1 Hz), 111.6 (d,
2JC−F = 22.2 Hz), 108.6, 106.7 (d,
3JC−F = 3.0 Hz), 82.8, 79.2, 62.6, 59.0, 57.4, 54.9, 49.50, 49.46, 34.9,
28.1, 27.5, 25.6, 22.1, 7.6, 7.5. HRMS (ESI+): calcd for
C36H44FN5O9S (M + H)
+ 742.2922, found 742.2930.
(6R,7R)-7-Acetamido-3-(((1-cyclopropyl-6-ﬂuoro-4-oxo-7-
(piperazin-1-yl)-1,4-dihydroquinoline-3-carbonyl)oxy)-
methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbox-
ylic Acid (35). Compound 34 (15 mg, 0.02 mmol) was dissolved in
anhydrous DCM (0.3 mL) and cooled to 0 °C. Anhydrous anisole (3
drops) was added followed by the dropwise addition of TFA (0.3
mL). The reaction mixture was stirred at 0 °C for 30 min, warmed to
room temperature, and stirred for a further 40 min. Solvent was
removed under a stream of N2 and the resulting gum triturated with
ice-cold EtOAc. The precipitate was collected, diluted in H2O and
DCM, and basiﬁed to pH 9 with 3% NaHCO3 (aq). The aqueous
phase was separated and loaded directly onto a 12 g SNAP KP-C18-
HS cartridge and puriﬁed by reverse-phase column chromatography
(0−100% MeCN in H2O). Fractions containing product were freeze-
dried to aﬀord the product as a white solid (2.5 mg, 23%). 1H NMR
(500 MHz, D2O) δ 8.58 (s, 1H), 7.73 (d, J = 13.0 Hz, 1H), 7.46 (d, J
= 7.2 Hz, 1H), 5.58 (d, J = 4.6 Hz, 1H), 5.11 (d, J = 12.6 Hz, 1H),
5.07 (d, J = 4.7 Hz, 1H), 4.81 (d, J = 12.6 Hz, 1H), 3.68−3.31 (m,
11H), 2.00 (s, 3H), 1.27 (d, J = 6.9 Hz, 2H), 1.06 (d, J = 4.3 Hz, 2H).
HRMS (ESI+): calcd for C27H29FN5O7S (M + H)
+ 586.1772, found
586.1794.
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